-

$undefined

N/A

(N/A)

Pyxis Oncology NASDAQ:PYXS Pyxis Oncology, Inc. is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. Pyxis develops its product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since its launch in 2019, Pyxis has developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates, and monoclonal antibody, or mAb, preclinical discovery programs that it is developing as monotherapies and in combination with other therapies.

Location: | Website: pyxisoncology.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-47.4M

Cash

126.9M

Avg Qtr Burn

-14.42M

Short % of Float

16.55%

Insider Ownership

23.72%

Institutional Own.

40.07%

Qtr Updated

12/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Micvotabart pelidotin (MICVO, formerly PYX-201) Details Cancer, r/m Head and neck squamous cell carcinoma (HNSCC) EGFRi & PD-1 Experienced	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Micvotabart pelidotin (MICVO, formerly PYX-201) Details Cancer, r/m Head and neck squamous cell carcinoma (HNSCC) 1/2L+	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Micvotabart pelidotin (MICVO, formerly PYX-201) Details Cancer, r/m Head and neck squamous cell carcinoma (HNSCC) 2/3L Platinum & PD-1 Experienced	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Micvotabart pelidotin (MICVO, formerly PYX-201) + Pembrolizumab Details Solid tumor/s (various)	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Micvotabart pelidotin (MICVO, formerly PYX-201) Details Head and neck cancer, Breast cancer, Thyroid cancer, Lung cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PYX-106 Details Colorectal cancer , Kidney cancer, Bladder cancer, Cholangiocarcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.